Company Website:
http://tokaipharma.com
CAMBRIDGE, Mass. -- (Business Wire)
Tokai Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company
focused on developing novel therapies for prostate cancer and other
hormonally-driven diseases, today announced the pricing of its initial
public offering of 6,480,000 shares of common stock at a public offering
price of $15.00 per share, before underwriting discounts and
commissions. All of the shares in the offering are being sold by Tokai.
In addition, Tokai has granted the underwriters a 30-day option to
purchase from the company, at the public offering price, less
underwriting discounts and commissions, up to an additional 972,000
shares of common stock. Tokai’s common stock is expected to begin
trading on The NASDAQ Global Market on Wednesday, September 17, 2014
under the ticker symbol “TKAI.”
BMO Capital Markets, Stifel and William Blair are acting as joint
book-running managers for the offering. Janney Montgomery Scott is
acting as co-manager.
A registration statement relating to these securities was declared
effective by the Securities and Exchange Commission on September 16,
2014. This offering is being made only by means of a prospectus. When
available, copies of the final prospectus relating to this offering may
be obtained by contacting: BMO Capital Markets Corp., Attention: Equity
Syndicate Department, 3 Times Square, 27th Floor, New York, NY 10036,
telephone: (800) 414-3627, email: bmoprospectus@bmo.com;
Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One
Montgomery Street, Suite 3700, San Francisco, CA 94104, telephone: (415)
364-2720, email: SyndicateOps@stifel.com;
or from William Blair & Company, L.L.C., Attention: Prospectus
Department, 222 West Adams Street, Chicago, IL 60606, telephone (800)
621-0687, email: prospectus@williamblair.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities, in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
Contacts:
Investor Contact:
Tokai Pharmaceuticals
Lee Kalowski,
617-225-4305
Chief Financial Officer
investors@tokaipharma.com
or
Media
Contact:
Pure Communications, Inc.
Sheryl Seapy, 949-903-4750
Sheryl@purecommunicationsinc.com
Source: Tokai Pharmaceuticals, Inc.
© 2024 Canjex Publishing Ltd. All rights reserved.